Healthcare [ 11/13 ] | Biotechnology [ 91/159 ]
NYSE | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 13, 24 | -1.03 Decreased by -243.33% | -0.5 Decreased by -106% |
| Nov 7, 23 | -0.58 Increased by +10.77% | -0.63 Increased by +7.94% |
| Aug 8, 23 | -0.58 Increased by +30.95% | -0.46 Decreased by -26.09% |
| May 9, 23 | -0.74 Decreased by -236.36% | -0.67 Decreased by -10.45% |
| Feb 28, 23 | -0.3 Increased by +33.33% | -0.29 Decreased by -3.45% |
| Nov 8, 22 | -0.65 Increased by +30.11% | -0.35 Decreased by -85.71% |
| Aug 9, 22 | -0.84 Increased by +12.5% | -0.91 Increased by +7.69% |
| May 9, 22 | -0.22 Increased by +52.17% | -0.7 Increased by +68.57% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 14.49 M Decreased by -81.01% | -47.81 M Increased by +5.53% | Decreased by -329.86% Decreased by -397.46% |
| Jun 30, 23 | 19.28 M Increased by +11.52% | -47.12 M Increased by +26.81% | Decreased by -244.34% Increased by +34.37% |
| Mar 31, 23 | 18.99 M Decreased by -59.16% | -59.43 M Decreased by -256.68% | Decreased by -312.9% Decreased by -773.25% |
| Dec 31, 22 | 69.8 M Increased by +310.34% | -24.16 M Increased by +29.74% | Decreased by -34.61% Increased by +82.88% |
| Sep 30, 22 | 76.32 M Increased by +480.52% | -50.61 M Increased by +29.27% | Decreased by -66.31% Increased by +87.82% |
| Jun 30, 22 | 17.29 M Increased by +359.87% | -64.37 M Increased by +11.29% | Decreased by -372.3% Increased by +80.71% |
| Mar 31, 22 | 46.5 M Increased by +N/A% | -16.66 M Increased by +67.67% | Decreased by -35.83% Decreased by N/A% |
| Dec 31, 21 | 17.01 M Decreased by -67.23% | -34.38 M Increased by +38.53% | Decreased by -202.12% Decreased by -87.56% |
ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.